We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
-15.65%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
AUM
$460M
AUM Growth
-$98.4M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$299M 65.12%
17,923,892
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$66.4M 14.44%
2,067,861
PCVX icon
3
Vaxcyte
PCVX
$7.81B
$47.9M 10.42%
1,887,478
MRUS
4
DELISTED
Merus
MRUS
$35.2M 7.66%
1,600,000
CMPI
5
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$5.96M 1.3%
1,501,716
OBSV
6
DELISTED
ObsEva SA Ordinary Shares
OBSV
$4.88M 1.06%
1,570,000

Similar funds

Medicxi Ventures Management's Q3 2021 Portfolio in Review

As of Q3 2021, Medicxi Ventures Management held 6 positions worth $460M, down 18% from $558M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 0%. Medicxi Ventures Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's ten largest holdings make up 100% of its $460M portfolio in Q3 2021.
  • Medicxi Ventures Management opened 0 new positions and closed 0 in Q3 2021.
  • Medicxi Ventures Management's portfolio value fell 18% quarter-over-quarter to $460M.

Based on Medicxi Ventures Management's 13F filing for Q3 2021, filed 10 Nov 2021.